Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Compare

983 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ADPT Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Adaptive

Biotechnologies

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ADPT Stock 12 Month Forecast

Average Price Target

$18.57

▲(31.70% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Adaptive Biotechnologies in the last 3 months. The average price target is $18.57 with a high forecast of $22.00 and a low forecast of $14.00. The average price target represents a 31.70% change from the last price of $14.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","23":"$23","8.75":"$8.75","13.5":"$13.5","18.25":"$18.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.75,13.5,18.25,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.36,17.716923076923077,18.073846153846155,18.43076923076923,18.787692307692307,19.144615384615385,19.501538461538463,19.858461538461537,20.215384615384615,20.572307692307692,20.92923076923077,21.286153846153844,21.643076923076922,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.36,17.45307692307692,17.546153846153846,17.639230769230767,17.732307692307693,17.825384615384614,17.91846153846154,18.01153846153846,18.104615384615386,18.197692307692307,18.290769230769232,18.383846153846154,18.47692307692308,{"y":18.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.36,17.10153846153846,16.84307692307692,16.584615384615383,16.326153846153847,16.067692307692308,15.80923076923077,15.55076923076923,15.292307692307691,15.033846153846154,14.775384615384615,14.516923076923078,14.258461538461539,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.31,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.36,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.00

Average Price Target$18.57

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Westenberg

Piper Sandler

$20

Buy

41.84%

Upside

Reiterated

11/11/25

Piper Sandler Remains a Buy on Adaptive Biotechnologies (ADPT)Life Science Tools & Labs ADPT trading at US$14.79 with an Overweight rating and a PT of $20.00; estimates revised and prior rating reiterated.

Tejas Savant

Morgan Stanley

$11→$16

Hold

13.48%

Upside

Reiterated

11/11/25

Adaptive Biotechnologies price target raised to $16 from $11 at Morgan StanleyAdaptive Biotechnologies price target raised to $16 from $11 at Morgan Stanley

William Bonello

Craig-Hallum

$18

Buy

27.66%

Upside

Assigned

11/06/25

Adaptive Biotechnologies (ADPT) Gets a Buy from Craig-Hallum

Daniel Brennan

TD Cowen

$15→$22

Buy

56.03%

Upside

Reiterated

11/06/25

Strong Q3 Performance and Market Position Drive Buy Rating for Adaptive BiotechnologiesWe continue to see a mult-year growth & margin story for this heme MRD leader. High-GM MRD ADPT's stock up 193% YTD, investors were optimistic for another strong result in 3Q, and we believe ADPT delivered. MRD sales grew 52% and were 15% ahead of expectations, with clinical MRD sales growing at 83%. In clinical, both volumes (+38% Y/Y; ahead of our 33%) and price (~30% Y/Y; ahead of our 19%) both were drivers. Sequencing Gross margins were ahead, and OpEx modestly below, leading EBITDA ex-Genentech non-cash items to ($6M) vs. our prior ($8.2M), with continued MRD leverage a highlight (2Q 4% to 3Q 12% with a $6.5M milestone). The full year revenue guide was raised by $10M, in line with the MRD upside in 3Q, and OpEx spending lowered, burn reduced.

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

11/06/25

Adaptive Biotechnologies: Strong Q3 Performance and Favorable Conditions Drive Buy RatingWe believe these should fuel volume and ASP growth for the business into 2026, and we struggle to tame our model that produces estimates that want to work their way higher.

Sebastian Sandler

J.P. Morgan

Not Ranked

J.P. Morgan

$17→$20

Buy

41.84%

Upside

Reiterated

11/06/25

Adaptive Biotechnologies price target raised to $20 from $17 at JPMorganAdaptive Biotechnologies price target raised to $20 from $17 at JPMorgan

Subbu Nambi

Guggenheim

$20

Buy

41.84%

Upside

Initiated

09/30/25

Adaptive Biotechnologies initiated with a Buy at GuggenheimAdaptive Biotechnologies initiated with a Buy at Guggenheim

Mark Massaro

BTIG

$14

Buy

-0.71%

Downside

Reiterated

08/19/25

Adaptive Biotechnologies: Strategic Flexibility and Robust MRD Growth Drive Buy Rating

Sung Ji Nam

Scotiabank

$12

Buy

-14.89%

Downside

Reiterated

05/05/25

Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)

Matthew Sykes

Goldman Sachs

$8→$9

Buy

-36.17%

Downside

Upgraded

03/21/25

Adaptive Biotechnologies (ADPT) was upgraded to a Buy Rating at Goldman Sachs

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Westenberg

Piper Sandler

$20

Buy

41.84%

Upside

Reiterated

11/11/25

Tejas Savant

Morgan Stanley

$11→$16

Hold

13.48%

Upside

Reiterated

11/11/25

Adaptive Biotechnologies price target raised to $16 from $11 at Morgan StanleyAdaptive Biotechnologies price target raised to $16 from $11 at Morgan Stanley

William Bonello

Craig-Hallum

$18

Buy

27.66%

Upside

Assigned

11/06/25

Adaptive Biotechnologies (ADPT) Gets a Buy from Craig-Hallum

Daniel Brennan

TD Cowen

$15→$22

Buy

56.03%

Upside

Reiterated

11/06/25

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

11/06/25

Sebastian Sandler

J.P. Morgan

Not Ranked

J.P. Morgan

$17→$20

Buy

41.84%

Upside

Reiterated

11/06/25

Adaptive Biotechnologies price target raised to $20 from $17 at JPMorganAdaptive Biotechnologies price target raised to $20 from $17 at JPMorgan

Subbu Nambi

Guggenheim

$20

Buy

41.84%

Upside

Initiated

09/30/25

Adaptive Biotechnologies initiated with a Buy at GuggenheimAdaptive Biotechnologies initiated with a Buy at Guggenheim

Mark Massaro

BTIG

$14

Buy

-0.71%

Downside

Reiterated

08/19/25

Adaptive Biotechnologies: Strategic Flexibility and Robust MRD Growth Drive Buy Rating

Sung Ji Nam

Scotiabank

$12

Buy

-14.89%

Downside

Reiterated

05/05/25

Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)

Matthew Sykes

Goldman Sachs

$8→$9

Buy

-36.17%

Downside

Upgraded

03/21/25

Adaptive Biotechnologies (ADPT) was upgraded to a Buy Rating at Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Adaptive Biotechnologies

1 Month

xxx

Success Rate

5/11 ratings generated profit

Average Return

+2.68%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 45.45% of your transactions generating a profit, with an average return of +2.68% per trade.

3 Months

xxx

Success Rate

8/11 ratings generated profit

Average Return

+9.08%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +9.08% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

9/12 ratings generated profit

Average Return

+65.32%

reiterated a buy rating 12 days ago

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +65.32% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+174.09%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +174.09% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ADPT Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ADPT has received 9 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ADPT average Analyst price target in the past 3 months is 18.57.

Each month's total comprises the sum of three months' worth of ratings.

ADPT Financial Forecast

ADPT Earnings Forecast

Next quarter’s earnings estimate for ADPT is -$0.18 with a range of -$0.20 to -$0.15. The previous quarter’s EPS was $0.06. ADPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ADPT has Performed in-line its overall industry.

ADPT Sales Forecast

Next quarter’s sales forecast for ADPT is $59.29M with a range of $57.74M to $61.50M. The previous quarter’s sales results were $93.97M. ADPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ADPT has Performed in-line its overall industry.

ADPT Stock Forecast FAQ

What is ADPT’s average 12-month price target, according to analysts?

Based on analyst ratings, Adaptive Biotechnologies Corp’s 12-month average price target is 18.57.

What is ADPT’s upside potential, based on the analysts’ average price target?

Adaptive Biotechnologies Corp has 31.70% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ADPT a Buy, Sell or Hold?

Adaptive Biotechnologies Corp has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Adaptive Biotechnologies Corp’s price target?

The average price target for Adaptive Biotechnologies Corp is 18.57. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $14.00. The average price target represents 31.70% Increase from the current price of $14.1.

What do analysts say about Adaptive Biotechnologies Corp?

Adaptive Biotechnologies Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of ADPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

ADPT Analyst Ratings

ADPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Adaptive Biotechnologies

ADPT Analyst Recommendation Trends

ADPT Financial Forecast

ADPT Earnings Forecast

ADPT Sales Forecast

ADPT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts